

Fig. 1: Top 20 Pharmaceutical Companies by US Sales '12

Rank	Company	2012 Total (Billions)	2011 Total (Billions)
1	Novartis	\$20.0	\$20.2
2	Merck	\$19.8	\$19.8
3	Pfizer	\$18.2	\$26.1
4	AstraZeneca	\$17.3	\$20.4
5	Teva	\$16.3	\$15.6
6	Roche	\$15.4	\$14.6
7	GlaxoSmithKline	\$14.1	\$14.7
8	Lilly	\$14.0	\$15.3
9	Amgen	\$13.9	\$13.4
10	Abbott*	\$12.5	\$12.0
11	Sanofi	\$12.1	\$12.4
12	Johnson & Johnson	\$12.0	\$12.1
13	Bristol-Myers Squibb	\$8.3	\$12.0
14	Boehringer Ingelheim	\$7.9	\$7.2
15	Actavis	\$7.7	\$6.0
16	Mylan	\$7.3	\$5.8
17	Gilead	\$6.7	\$5.6
18	Novo Nordisk	\$6.6	\$5.4
19	Otsuka	\$6.0	\$5.3
20	Takeda	\$5.5	\$7.1
Total others		\$84.4	\$78.0
Total market		\$325.8	\$329.2

Source: IMS Health, National Sales Perspectives *On January 2, 2013, Abbott's research-based pharma business, AbbVie, became a separate entity